All News

Iron Deficiency Anemia Therapy Market 2027 : Size, Share, Growth, Analysis including Key players Bayer AG, Sanofi S.A…

Iron Deficiency Anemia Therapy Market

The Global Iron Deficiency Anemia Therapy market size is predicted to experience promising growth owing to the high prevalence of anemia worldwide, shares Fortune Business Insights™ in its report, titled “Iron Deficiency Anemia Therapy Market Size, Share & Industry Analysis, By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others), By End User (Hospitals, Clinics, Homecare Settings) and Regional Forecast, 2020-2027”. A study conducted by the World Health Organization (WHO) between 1993 and 2005 found that 1.62 billion people, or 24.8% of the global population, suffer from anemia, with the highest incidence witnessed in non-pregnant women. The prevalence of iron deficiency anemia (IDA) is particularly high in poorer countries. For example, according to a 2017 study conducted by researcher from the Indira Gandhi Institute of Medical Sciences, Bihar, India showed that 50% of the adolescent girls surveyed for the study had IDA. Of these, 3.3% were severely anemic. The main reason for these shocking numbers is the lack of iron intake through regular food and loss of blood during menstruation and pregnancy. Iron deficiency anemia therapies can play a critical role in providing the necessary nutrients to prevent the development of anemia in girls and other vulnerable sections. Moreover, these therapies can help mitigate the adverse effects of IDA and restore the health of the affected persons.
What Does the Report Offer?
• Granular examination of the top market trends, drivers, and restraints;
• Detailed analysis of the key market segments;
• In-depth assessment of the regional developments influencing the market dynamics; and
• Comprehensive profiling and evaluation of the major industry players and their key strategies.

Driving Factor
COVID-19 May Heighten the Need for IDA Therapies
The SARS-CoV-2 infection has been proven to have particularly severe effects on people with comorbidities such as diabetes and heart disease. Iron deficiency anemia is also considered to be a comorbidity, which weakens the immune system. According to recent research by the Pelita Harapan University in Indonesia, patients with anemia are at a heightened risk of developing severe COVID-19 infection. Since patients with anemia have low hemoglobin levels, their ability to fight infections is substantially lowered. With organs not receiving sufficient amounts of oxygen, the risk of multi-organ failure in anemic patients automatically increases. COVID-19, the research found, can worsen anemic conditions. For example, the virus can interact and attack the hemoglobin molecules, causing hemolysis. Furthermore, the virus can also lead to tissue ferritin, which mainly impacts the liver, bone marrow, spleen, and muscles, leading to a cytokine storm (immune over-response) and aggravate the infection as well as the anemia. Thus, iron deficiency anemia therapies are likely to experience heightened demand during the coronavirus pandemic as physicians will need to provide quick and effective treatment to anemic patients showing signs of the COVID-19 infection.

Regional Insights
Increasing Testing of Women for Anemia to Stimulate Market Growth in North America
Geographically, North America is expected to lead the iron deficiency anemia therapy market share in the forthcoming years on account of the steadily expanding testing of women for anemia in Canada and the US. This factor is underpinned by the spreading awareness about the importance of women’s health in the region and increased spending on developing healthcare facilities suited for women. Asia Pacific is anticipated to register the highest CAGR owing to the improving knowledge about the high incidence of IDA in women and the rising focus of governments towards the betterment of health of women. In Europe, increasing adoption of advanced IDA therapies and strong healthcare infrastructure will favor the regional market growth.

Click here to request a sample copy of the Research Report

Competitive Landscape
Key Players to Benefit from the Favorable Regulatory Climate for IDA Treatments
Recognizing the urgency of releasing therapies to tackle the growing prevalence of iron deficiency anemia, regulatory bodies are providing the necessary support to approve novel IDA therapies developed by some of the key players in the market. These approvals are encouraging other competitors to ramp up their R&D spending and come up with innovative offerings.

Industry Development:
• January 2020: Pharmacosmos Therapeutics received clearance from the US Food and Drug Administration (FDA) for its ferric derisomaltose (Monoferric®). The treatment has been designed for adult patients suffering from IDA, who have intolerance for oral iron or patients who have non-hemodialysis dependent chronic kidney disease.

List of Key Players Covered in the Iron Deficiency Anemia Therapy Market Report:
• Acceleron Pharma, Inc.
• Bayer AG
• Pieris
• Allergan (AbbVie)
• Apotex Inc.
• AMAG Pharmaceuticals
• Sanofi S.A.
Enquire before buying:

About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: [email protected]

About the Author
Name: Shantanu Ayachit
Shantanu Ayachit is part of a talented team of content writers working in Fortune Business Insights™, one of the most promising market research firms in the industry. He has experience in developing quality content and is currently involved in writing articles, press releases, and blogs for the company. He is highly motivated and enjoys putting ideas and thoughts into words to enable the reader to experience a seamless perusal.